Quick Facts: Therapeutic Domains

• Utilized as a temporary aid to facilitate tracheal intubation.
• Intended to assist with skeletal muscle relaxation during surgical procedures.
• Employed as an adjunct to mechanical ventilation in the Intensive Care Unit (ICU).

Эсмерон (Rocuronium bromide) is a medication administered as an adjunct to general anesthesia. Its principal therapeutic role is to facilitate the temporary relaxation of skeletal muscles. This effect is instrumental in clinical settings that require the patient's muscles to be still and relaxed.

Key applications involve supporting procedures that require the placement of an artificial breathing tube (tracheal intubation). This includes both routine surgical preparation and rapid sequence induction techniques. Furthermore, the medication may be used to provide necessary muscle relaxation during the course of various surgical procedures, thereby supporting the efforts of the surgical team.

In the critical care environment, Rocuronium bromide is also utilized to maintain muscle relaxation to facilitate mechanical ventilation, which can be a key component of patient management in the Intensive Care Unit. The administration and monitoring of this therapy require close supervision by qualified healthcare professionals.

Who can and cannot use Эсмерон? (Rocuronium Bromide)

The eligibility for Rocuronium Bromide is strictly defined by regulatory authorities based on patient profile and clinical condition. The medicine is primarily indicated for use in adults and pediatric patients (from term neonates) for routine procedures.

---

Eligibility Scope

Category	Official Regulatory Status
Contraindicated Populations	Patients with known hypersensitivity (allergy) to Rocuronium Bromide or the bromide ion.
Conditional Use	Patients with hepatic or renal impairment (due to risk of prolonged effect) and those with neuromuscular diseases (due to increased sensitivity).
Use Not Recommended	Pediatric patients for rapid sequence intubation; Pregnant patients for rapid sequence induction during Cesarean section; and use during breastfeeding.

---

Eligibility-Related Restrictions

Category	Regulatory Constraint
Age-Related	Geriatric patients may exhibit a prolonged effect and are at increased risk for residual neuromuscular block.
Reproductive Status	Use during pregnancy is permitted only if the potential benefit justifies the potential risk.
Context Constraint	Administration must be accompanied by adequate anesthesia or sedation and immediate availability of facilities for mechanical ventilation.

Connection to the overall eligibility profile

Official labeling defines an absolute contraindication only for patients with known hypersensitivity. All other limitations define populations requiring conditional or restricted use based on organ health, clinical status, or developmental stage, such as those with hepatic impairment or specific pediatric groups.

Interactions with other medicines and products

Regulatory information documents that the activity of Эсмерон (Rocuronium Bromide) may be significantly modified by co-administered agents, resulting in either potentiation (enhanced effect) or resistance (reduced effect) of the neuromuscular block.

Interactions Resulting in Potentiation (Enhanced Effect):

Product Category	Specific Examples	Documented Outcome
Inhalation Anesthetics	Isoflurane, Sevoflurane	Prolongation of action; decrease in required infusion rate (up to 40%).
Certain Antibiotics	Aminoglycosides, Vancomycin, Polymyxins	Prolongation of neuromuscular block (Source 3.1).
Other Agents	Magnesium salts, Lithium Carbonate, Procainamide	Increased duration of neuromuscular block (Source 3.1).

Interactions Resulting in Resistance (Reduced Effect):

Product Category	Specific Examples	Documented Outcome
Chronic Anticonvulsant Therapy	Phenytoin, Carbamazepine	Apparent resistance, leading to shortened clinical duration (Source 3.1).
Reversal Agents	Acetylcholinesterase Inhibitors (e.g., Neostigmine)	Antagonism of the neuromuscular block (Source 1.4).

Timing and Population-Specific Notes:

• Timing: Regulatory labels advise against administering Эсмерон until recovery is evident from a prior Succinylcholine block (Source 1.7).
• Hepatic Impairment: Patients with hepatic disease may experience a prolonged duration of effect due to slower drug clearance (Source 2.2).
• Concurrent Use: Long-term concurrent use of Эсмерон with Corticosteroids in the Intensive Care Unit (ICU) setting is associated with a specific risk of myopathy (Source 2.5).

️ Molecular Targeting and Competitive Action

The mechanism of Эсмерон is defined by competitive antagonism at the Post-junctional Nicotinic Acetylcholine Receptors ( N M subtype) on the muscle's motor end-plate. The drug binds directly to these peripheral receptors, physically blocking the natural neurotransmitter, Acetylcholine ( ACh), from initiating a signal.

---

The Signal Interruption Cascade

By preventing ACh binding, the drug halts the necessary sodium ion ( Na^+) influx, thus inhibiting the electrical excitation of the muscle cell and leading directly to loss of electrical excitability across the skeletal muscle system. This cascade is strictly peripheral, ensuring the drug's action is confined to the motor system without affecting consciousness or central brain activity.

---

Mechanism Specificity and Reversibility

The focused nature of the blockade dictates a defined physiological response. The competitive antagonism mechanism permits active, on-demand reversal by agents that either increase the local concentration of ACh or selectively encapsulate the Rocuronium molecule in the plasma, making the cessation of the physiological effect possible via external agents.

How Эсмерон is Used: Administration Guidelines

Эсмерон (Rocuronium Bromide) administration is restricted to the intravenous (IV) route and must occur within a specialized clinical environment where the patient's respiratory function can be continuously supported. The medicine is delivered either as a single, rapid IV injection (bolus) or as a continuous IV infusion for prolonged procedures or use in the Intensive Care Unit (ICU).

Dosage and Frequency

Initial dosing is strictly weight-based, with two primary regimens determining the speed of action. The standard dose for routine tracheal intubation is 0.6 mg/kg of body weight. For procedures requiring a very fast onset, such as Rapid Sequence Induction (RSI), a higher dose of 1.0 mg/kg is utilized.

Maintenance dosing—either via intermittent bolus injections of 0.1 to 0.2 mg/kg or a continuous infusion, typically starting at 0.3 to 0.6 mg/kg/hour—is not based on fixed time intervals. Instead, subsequent doses or adjustments to the infusion rate are governed entirely by continuous objective monitoring of the patient's muscle function using a nerve stimulator.

Administration Conditions

Clinical guidelines specify that Rocuronium Bromide must only be administered after the patient has received adequate general anesthesia or sedation, as the medication induces paralysis without affecting consciousness. For continuous infusion, the solution may be diluted with standard IV fluids, such as 0.9% Sodium Chloride or 5% Glucose, before administration.

Population-Specific Rules

Specific dosing modifications are required for certain populations. The initial dose for older adults or patients with hepatic/biliary disease should typically be the lower 0.6 mg/kg regimen due to the potential for a prolonged effect. Pediatric patients also require distinct weight-based dosage calculations specific to their age group.

Research Evidence / Overview of Studies for Эсмерон (Rocuronium Bromide)

---

Эсмерон and Routine Tracheal Intubation

Research has widely explored Rocuronium Bromide (Эсмерон) as a tool to temporarily relax muscles when a breathing tube needs to be placed during routine general anesthesia. These evaluations primarily involve Randomized Controlled Trials (RCTs) and scientific reviews, which are commonly used to evaluate drug properties in a controlled manner. Studies monitored the onset time, or how quickly the necessary level of muscle relaxation was reached for intubation, and used standardized scoring systems to measure the intubation conditions using established research scales.

The findings described patterns related to the time it takes for the onset of muscle relaxation, which is a primary outcome measured in these studies. Long-term outcomes related to muscle function are not well characterized, as follow-up durations were strictly limited to the perioperative period.

---

Эсмерон in Rapid Sequence Intubation (RSI)

Dedicated comparative research, including RCTs and meta-analyses, has also examined Rocuronium Bromide's use in the rapid sequence induction (RSI) technique. This technique is used when a fast, nearly immediate relaxation of muscles is needed to facilitate intubation in situations requiring a rapid onset. These studies monitored the specific timeframe during which intubation readiness was measured, typically 60 to 90 seconds.

Research examined patterns related to the specific muscle relaxation scores measured during RSI. Studies explored and reported the frequency of measured intubation conditions when compared against other rapid-acting agents. Evidence is limited for this specific use in pediatric populations, and data for that group remain insufficient.

---

Evidence for Muscle Relaxation During Surgery and ICU Ventilation

Research has explored the use of Rocuronium Bromide beyond the initial intubation phase. Furthermore, the medication was evaluated in critical care settings, where it may be used to maintain muscle relaxation as an adjunct to mechanical ventilation in critically ill adult patients in the Intensive Care Unit (ICU).

Studies monitored the infusion rates administered for the purpose of maintaining muscle relaxation. Data described patterns of recovery time, including instances of slower spontaneous recovery that was observed in some studies involving specific patients, such as those with existing kidney or liver conditions. Robust, large-scale evidence is limited for the prolonged, continuous use of the medication over multiple days in the ICU setting.

Key Studies & References

1. Rocuronium - StatPearls - NCBI Bookshelf

Common questions about Эсмерон (FAQ)

---

Q: For what medical procedures is Esmeron (Rocuronium Bromide) typically used?

Regulatory documents indicate that Esmeron is used as a muscle relaxant to assist with endotracheal intubation—placing a breathing tube—during general anesthesia, including for rapid-sequence procedures. It is also utilized to maintain muscle relaxation throughout various surgical procedures and for patients requiring long-term mechanical ventilation in the intensive care unit (ICU).

---

Q: How long does Esmeron take to start working after it is administered?

According to the official product information, Esmeron is characterized by a rapid onset of action. The time it takes for the maximum effect of the drug to be observed is usually under 90 seconds. Its rapid onset, typically under 90 seconds, is a key characteristic noted in the official product information.

---

Q: How is Esmeron administered to a patient?

Official product information states that Esmeron is an intravenous (IV) medicine, meaning it is administered directly into a vein under professional supervision. It is generally given either as a bolus injection (a single dose over a short time) or through a continuous intravenous infusion (a steady drip) during the procedure.

---

Q: Can Esmeron be used in children for surgical procedures?

Studies and official information indicate that Esmeron can be used in pediatric patients, encompassing term neonates (newborns) through adolescents, for purposes like routine intubation and muscle relaxation maintenance. Its use in pediatric patients is subject to the specific guidelines and professional discretion outlined in the product labeling.

---

Q: Is it possible to reverse the effects of Esmeron?

Yes, regulatory documents confirm that the effects of Esmeron, a non-depolarizing neuromuscular blocking agent, can be reversed. This reversal is performed using specific medications, such as sugammadex or neostigmine, which are used to facilitate the return of muscle function following the procedure.

---

Q: What happens if a patient has a known allergy to rocuronium bromide or the bromide ion?

According to the official product information, Esmeron is contraindicated—meaning it should not be used—in patients with a known hypersensitivity (allergy) to the active substance, rocuronium bromide, or to the bromide ion. A patient's history of hypersensitivity to these substances is a primary consideration for the administering medical team, according to regulatory documents.

---

Q: Can Esmeron affect the heart rate or blood pressure?

Official product information indicates that Esmeron can potentially affect the cardiovascular system. Regulatory documents note that changes such as a temporary increase in heart rate (tachycardia) or a decrease in blood pressure (hypotension) have been reported, particularly when higher doses are administered rapidly.

---

Q: Does Esmeron have any specific storage or handling requirements?

Yes, official product information provides specific guidance on storage for Esmeron. Unopened vials must be stored in a refrigerator at temperatures between 2 C and 8 C. The medicine should not be allowed to freeze. The labeling also includes instructions for the appropriate handling and disposal of any unused portions.

Storing and Disposing of Esmeron (Rocuronium Bromide)

The storage and handling of Esmeron are defined by strict regulatory requirements to ensure product integrity.

Official Storage Conditions

Requirement	Condition
Temperature	Store in a refrigerator between 2 C and 8 C.
Freezing	Do not freeze the solution.
Protection	Store in the original container and protect from light.

Stability and Handling

The unopened vial has a regulatory shelf-life of 3 years under refrigerated conditions. Vials may be stored outside of the refrigerator at room temperature (up to 30 C) for a single, maximum period of 12 weeks. Diluted solutions must be used immediately due to microbiological safety, though chemical stability is demonstrated for 24 hours.

Disposal and Child Safety

Esmeron must be kept out of the sight and reach of children. Any unused product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste and must not be discarded into household waste or wastewater.